JP2016530268A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530268A5 JP2016530268A5 JP2016535272A JP2016535272A JP2016530268A5 JP 2016530268 A5 JP2016530268 A5 JP 2016530268A5 JP 2016535272 A JP2016535272 A JP 2016535272A JP 2016535272 A JP2016535272 A JP 2016535272A JP 2016530268 A5 JP2016530268 A5 JP 2016530268A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- inhibitor
- use according
- mammal
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013903189 | 2013-08-22 | ||
| AU2013903189A AU2013903189A0 (en) | 2013-08-22 | Immunomodulator | |
| AUPCT/AU2013/001132 | 2013-10-03 | ||
| PCT/AU2013/001132 WO2015024042A1 (en) | 2013-08-22 | 2013-10-03 | Immunoreceptor modulation for treating cancer and viral infections |
| AU2014900741 | 2014-03-05 | ||
| AU2014900741A AU2014900741A0 (en) | 2014-03-05 | Immunoreceptor modulation for treating cancer and viral infections | |
| AU2014901002A AU2014901002A0 (en) | 2014-03-21 | Immunoreceptor modulation for treating cancer and viral infections | |
| AU2014901002 | 2014-03-21 | ||
| PCT/AU2014/000830 WO2015024060A1 (en) | 2013-08-22 | 2014-08-22 | Immunoreceptor modulation for treating cancer and viral infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019205385A Division JP2020059714A (ja) | 2013-08-22 | 2019-11-13 | 癌及びウイルス感染症を治療するための免疫受容体調節 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530268A JP2016530268A (ja) | 2016-09-29 |
| JP2016530268A5 true JP2016530268A5 (enExample) | 2017-10-05 |
| JP6618908B2 JP6618908B2 (ja) | 2019-12-11 |
Family
ID=52482836
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016535272A Active JP6618908B2 (ja) | 2013-08-22 | 2014-08-22 | 免疫抑制を低減又は軽減するためのｃｄ９６阻害抗体又は抗体断片の使用 |
| JP2019205385A Pending JP2020059714A (ja) | 2013-08-22 | 2019-11-13 | 癌及びウイルス感染症を治療するための免疫受容体調節 |
| JP2022012145A Pending JP2022044808A (ja) | 2013-08-22 | 2022-01-28 | 癌及びウイルス感染症を治療するための免疫受容体調節 |
| JP2023134163A Pending JP2023156487A (ja) | 2013-08-22 | 2023-08-21 | 癌及びウイルス感染症を治療するための免疫受容体調節 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019205385A Pending JP2020059714A (ja) | 2013-08-22 | 2019-11-13 | 癌及びウイルス感染症を治療するための免疫受容体調節 |
| JP2022012145A Pending JP2022044808A (ja) | 2013-08-22 | 2022-01-28 | 癌及びウイルス感染症を治療するための免疫受容体調節 |
| JP2023134163A Pending JP2023156487A (ja) | 2013-08-22 | 2023-08-21 | 癌及びウイルス感染症を治療するための免疫受容体調節 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20160208000A1 (enExample) |
| EP (1) | EP3036258B1 (enExample) |
| JP (4) | JP6618908B2 (enExample) |
| KR (3) | KR20230085220A (enExample) |
| CN (1) | CN105636985A (enExample) |
| BR (1) | BR112016003532A8 (enExample) |
| CA (1) | CA2921774C (enExample) |
| DK (1) | DK3036258T3 (enExample) |
| ES (1) | ES2967538T3 (enExample) |
| FI (1) | FI3036258T3 (enExample) |
| HK (1) | HK1225396A1 (enExample) |
| HR (1) | HRP20231186T1 (enExample) |
| HU (1) | HUE063307T2 (enExample) |
| MX (1) | MX2016002263A (enExample) |
| MY (1) | MY192043A (enExample) |
| NZ (1) | NZ717534A (enExample) |
| PL (1) | PL3036258T3 (enExample) |
| SG (1) | SG11201601283PA (enExample) |
| SI (1) | SI3036258T1 (enExample) |
| WO (1) | WO2015024060A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013398294A1 (en) * | 2013-08-22 | 2016-03-17 | The Council Of The Queensland Institute Of Medical Research | Immunoreceptor modulation for treating cancer and viral infections |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| ES3040431T3 (en) | 2014-03-12 | 2025-10-31 | Yeda Res & Dev | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| MY187045A (en) | 2014-12-23 | 2021-08-27 | Bristol Myers Squibb Co | Antibodies to tigit |
| CN116064401A (zh) * | 2015-07-29 | 2023-05-05 | 昂克医疗有限公司 | 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系 |
| EP3344656A1 (en) | 2015-09-01 | 2018-07-11 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
| KR20250099459A (ko) | 2015-11-03 | 2025-07-01 | 얀센 바이오테크 인코포레이티드 | Pd-1과 특이적으로 결합하는 항체 및 그의 용도 |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| CN118634323A (zh) | 2016-12-07 | 2024-09-13 | 艾吉纳斯公司 | 抗体和其使用方法 |
| CA3072394A1 (en) * | 2017-08-11 | 2019-02-14 | Blink Biomedical Sas | Cd96-binding agents as immunomodulators |
| US20200347130A1 (en) | 2017-11-10 | 2020-11-05 | Jiangsu Hengrui Medicine Co., Ltd. | CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| AR117327A1 (es) | 2018-12-20 | 2021-07-28 | 23Andme Inc | Anticuerpos anti-cd96 y métodos de uso de estos |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| KR20220053007A (ko) | 2019-08-30 | 2022-04-28 | 아게누스 인코포레이티드 | 항-cd96 항체 및 이의 사용 방법 |
| BR112022005787A2 (pt) * | 2019-09-27 | 2022-06-21 | Glaxosmithkline Ip Dev Ltd | Proteínas de ligação a antígeno |
| JP7576847B2 (ja) * | 2019-10-30 | 2024-11-01 | 国立大学法人 筑波大学 | 免疫応答抑制剤 |
| WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
| TW202304965A (zh) | 2021-05-04 | 2023-02-01 | 美商艾吉納斯公司 | 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法 |
| CN116377061B (zh) * | 2022-11-28 | 2024-01-16 | 中山大学孙逸仙纪念医院 | 乳腺癌新辅助化疗耐药标志物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1481993A1 (en) | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
| WO2005107799A1 (ja) * | 2004-05-06 | 2005-11-17 | Eisai R & D Management Co., Ltd. | 抗Necl-5抗体を有効成分として含む癌治療剤 |
| WO2008073316A2 (en) * | 2006-12-07 | 2008-06-19 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and isolation of acute myeloid leukemia stem cells |
| EP3208612B1 (en) * | 2008-04-09 | 2019-09-18 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US9149544B2 (en) * | 2009-11-06 | 2015-10-06 | The Penn State Research Foundation | Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo |
| CN102204901A (zh) | 2010-03-30 | 2011-10-05 | 中国科学院上海生命科学研究院 | 调节免疫分子的试剂和方法 |
| AU2013355379B2 (en) * | 2012-12-04 | 2018-08-09 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| RU2725542C2 (ru) * | 2013-05-13 | 2020-07-02 | Селлектис | Способы конструирования высокоактивных т-клеток для иммунотерапии |
-
2014
- 2014-08-22 CA CA2921774A patent/CA2921774C/en active Active
- 2014-08-22 NZ NZ717534A patent/NZ717534A/en not_active IP Right Cessation
- 2014-08-22 MX MX2016002263A patent/MX2016002263A/es unknown
- 2014-08-22 KR KR1020237018788A patent/KR20230085220A/ko not_active Ceased
- 2014-08-22 FI FIEP14838641.0T patent/FI3036258T3/fi active
- 2014-08-22 HR HRP20231186TT patent/HRP20231186T1/hr unknown
- 2014-08-22 KR KR1020167007435A patent/KR20160055819A/ko not_active Ceased
- 2014-08-22 KR KR1020257003382A patent/KR20250024106A/ko active Pending
- 2014-08-22 ES ES14838641T patent/ES2967538T3/es active Active
- 2014-08-22 SI SI201432042T patent/SI3036258T1/sl unknown
- 2014-08-22 PL PL14838641.0T patent/PL3036258T3/pl unknown
- 2014-08-22 US US14/913,348 patent/US20160208000A1/en not_active Abandoned
- 2014-08-22 BR BR112016003532A patent/BR112016003532A8/pt not_active Application Discontinuation
- 2014-08-22 JP JP2016535272A patent/JP6618908B2/ja active Active
- 2014-08-22 EP EP14838641.0A patent/EP3036258B1/en active Active
- 2014-08-22 WO PCT/AU2014/000830 patent/WO2015024060A1/en not_active Ceased
- 2014-08-22 CN CN201480052069.7A patent/CN105636985A/zh active Pending
- 2014-08-22 MY MYPI2016000314A patent/MY192043A/en unknown
- 2014-08-22 DK DK14838641.0T patent/DK3036258T3/da active
- 2014-08-22 HU HUE14838641A patent/HUE063307T2/hu unknown
- 2014-08-22 HK HK16113673.9A patent/HK1225396A1/zh unknown
- 2014-08-22 SG SG11201601283PA patent/SG11201601283PA/en unknown
-
2019
- 2019-11-13 JP JP2019205385A patent/JP2020059714A/ja active Pending
-
2020
- 2020-07-24 US US16/938,214 patent/US20210047403A1/en active Pending
-
2022
- 2022-01-28 JP JP2022012145A patent/JP2022044808A/ja active Pending
-
2023
- 2023-08-21 JP JP2023134163A patent/JP2023156487A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530267A5 (enExample) | ||
| HRP20231186T1 (hr) | Modulacija imunoreceptora za liječenje raka i virusnih infekcija | |
| PH12019502356A1 (en) | Trem2 antigen binding proteins and uses thereof | |
| JOP20200312A1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
| JOP20200137B1 (ar) | نظائر إنكريتين واستخداماتها | |
| RU2015123032A (ru) | Иммунотерапия с применением связывающих агентов | |
| JOP20200136B1 (ar) | نظائر إنكريتين واستخداماتها | |
| JP2011157378A5 (enExample) | ||
| NZ601943A (en) | Antibodies against cxcr4 | |
| JP2018520679A5 (enExample) | ||
| MX2020012416A (es) | Anticuerpos dirigidos contra il-33 y sus usos. | |
| WO2018191548A3 (en) | Complement factor d antagonist antibodies and conjugates thereof | |
| JP2019520550A5 (enExample) | ||
| JP2015535691A5 (enExample) | ||
| TW201613970A (en) | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy | |
| EA201200795A1 (ru) | Связывающие элементы для пептида с5а с высоким ингибирующим действием | |
| JP2011524741A5 (enExample) | ||
| GB2496337A (en) | Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases | |
| MX2018013517A (es) | Anticuerpos anti-il-1r3 humanizados. | |
| JP2014087372A5 (enExample) | ||
| JP2017508744A5 (enExample) | ||
| WO2015112836A3 (en) | Antibodies against f glycoprotein of hendra and nipah viruses | |
| JP2017537972A5 (enExample) | ||
| CN111542546A (zh) | 抗lag-3 抗体及其用途 | |
| JP2017521445A5 (enExample) |